Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 3;68(4):e0154823.
doi: 10.1128/aac.01548-23. Epub 2024 Feb 28.

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Christophe Le Terrier  1   2 , Patrice Nordmann  1   3 , Chloé Buchs  1 , Laurent Poirel  1   3
Affiliations

Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases

Christophe Le Terrier et al. Antimicrob Agents Chemother. .

Abstract

The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to β-lactam/β-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and to cefiderocol. A large series of E. coli recombinant strains producing broad-spectrum β-lactamases was evaluated. While imipenem-relebactam showed a similar activity regardless of the PBP3 background, susceptibility to other molecules tested was affected at various levels. This was particularly the case for ceftazidime-avibactam, aztreonam-avibactam, and cefepime-taniborbactam.

Keywords: PBP3; YRIK; YRIN; avibactam; cefiderocol; relebactam; susceptibility testing; taniborbactam; vaborbactam; β-lactamase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. 2015. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13:42–51. doi:10.1038/nrmicro3380 - DOI - PubMed
    1. Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. 2023. In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of Gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program. Antimicrob Agents Chemother 67:e0128122. doi:10.1128/aac.01281-22 - DOI - PMC - PubMed
    1. Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual Á, Tormo N, Cantón R. 2022. In vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain. Antimicrob Agents Chemother 66:e0216121. doi:10.1128/aac.02161-21 - DOI - PMC - PubMed
    1. Le Terrier C, Freire S, Nordmann P, Poirel L. 2024. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives? Eur J Clin Microbiol Infect Dis 43:339–354. doi:10.1007/s10096-023-04732-4 - DOI - PMC - PubMed
    1. Nordmann P, Poirel L. 2019. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis 69:S521–S528. doi:10.1093/cid/ciz824 - DOI - PMC - PubMed

Publication types

Grants and funding

LinkOut - more resources